Ulcen

Quick links to important sections

Ulcen

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ulcen

Understanding Ulcen

Ulcen is a medication belonging to the class of drugs known as histamine-2 (H2) receptor antagonists. It is primarily used to manage conditions related to the overproduction of stomach acid. By reducing the volume and acidity of gastric juices, it helps alleviate discomfort and promotes the healing of the digestive lining.

Mechanism of Action

The stomach contains specialized cells called parietal cells, which are responsible for secreting hydrochloric acid. These cells have receptors for histamine; when histamine binds to these receptors, it signals the cell to produce acid.

Ulcen works by competitively blocking these H2 receptors. By preventing histamine from binding, the medication effectively decreases the amount of acid released into the stomach environment. This reduction in acidity is a key factor in managing acid-related disorders.

Common Applications

Ulcen is utilized in several clinical scenarios where the control of gastric acid is necessary:

  • Gastric and Duodenal Ulcers: It is used to treat active ulcers in the stomach or the upper part of the small intestine (duodenum) and may be used as a maintenance therapy to prevent their recurrence.
  • Gastroesophageal Reflux Disease (GERD): The medication helps manage symptoms such as heartburn and acid regurgitation by limiting the acid that can back up into the esophagus.
  • Hypersecretory Conditions: It is used for rare conditions characterized by excessive acid production, such as Zollinger-Ellison syndrome.
  • Erosive Esophagitis: It aids in the healing of inflammation or damage to the esophageal lining caused by chronic acid exposure.

What side effects are possible with Ulcen?

Possible Side Effects and Safety Information

The safety profile for Ulcen (Aluminium Silicate) is primarily defined by its local action in the gastrointestinal tract and the potential consequences of its mineral components, as documented by official health authorities.

Classification Regulatory Safety Description
Common Adverse Reactions The most frequently observed local effect is constipation, which is an expected gastrointestinal consequence of the compound's adsorbent properties.
System-Organ Classes Effects are officially noted in Gastrointestinal Disorders, Metabolism and Nutrition Disorders, Nervous System Disorders, and Musculoskeletal Disorders.
Duration-Related Risks Systemic adverse effects are associated with long-term or excessive chronic use, not with acute, short-term treatment.

Serious adverse reactions are related to the accumulation of aluminium in the body. This risk is primarily documented in individuals with severe renal impairment due to the kidney's role in clearing the compound. In this specific population, failure to excrete the compound can lead to serious conditions, including neurotoxicity (such as dialysis encephalopathy) and bone toxicity (osteomalacia).

Adherence to official safety standards also notes the compound's capacity to act as a safety constraint by physically binding to other orally administered medicines. This adsorbent action may reduce the absorption of other medicines, a high-level safety consideration documented for this class of product. The risk of hypophosphatemia (phosphate depletion) is also officially documented as a concern tied to prolonged intake, impacting metabolic and nutritional balance.

The overall regulatory safety structure emphasizes that the most severe risks are highly conditional upon both the duration of use and the pre-existing health status of the individual.

Overdose and Emergency Response

Ulcen Overdose and when to seek help

Documented Overdose Profile

The officially documented overdose profile for Ulcen (Aluminium Silicate) reflects its nature as a local-acting compound.

Feature Regulatory Status
Documented Manifestation Non-specific presentations primarily involve gastrointestinal tract irritation. No severe systemic signs are universally documented in acute oral overdose.
Acute Hazard Classification The compound is classified by public health agencies as a low acute oral hazard following massive ingestion.
Antidote Availability No specific antidote is known for overdose with this compound.
Treatment Strategy Management is defined as symptomatic and supportive treatment.

Regulatory Mandate for Emergency Action

In the event of an ingestion suspected to be an overdose, official regulatory guidance mandates that medical advice must be sought immediately. This instruction is required following accidental or massive ingestion to allow a healthcare professional to determine the appropriate response and assess the potential degree of gastrointestinal irritation.

Connection to the Overall Overdose Profile

The official regulatory profile is defined by the compound's low acute systemic toxicity and the resulting mandate for symptomatic and supportive measures. Due to the absence of documented severe systemic outcomes, the principal instruction is to contact medical professionals immediately to manage localized effects, consistent with the fact that no specific antidote is known.

Therapeutic Uses of Ulcen

What Ulcen Treats

Ulcen is a medication belonging to the class of proton pump inhibitors (PPIs). It is primarily used to manage conditions related to excessive stomach acid production, which can cause damage to the lining of the digestive tract and lead to uncomfortable symptoms.

Main Uses

  • Gastric and Duodenal Ulcers: Ulcen is used to facilitate the healing of ulcers in the stomach (gastric) and the first part of the small intestine (duodenal). By reducing acid levels, it allows the damaged tissue to repair itself.
  • Gastroesophageal Reflux Disease (GERD): This condition occurs when stomach acid frequently flows back into the tube connecting your mouth and stomach (esophagus). Ulcen helps manage symptoms like heartburn and prevents further irritation or inflammation of the esophageal lining.
  • Erosive Esophagitis: For patients whose esophagus has been physically damaged by acid reflux, this medication helps reduce acidity to promote healing and prevent future recurrence of erosions.
  • Zollinger-Ellison Syndrome: Ulcen is utilized in the management of rare pathological hypersecretory conditions where the stomach produces abnormally high amounts of acid.
  • NSAID-Associated Ulcers: It may be used to treat or reduce the risk of ulcers in patients who require long-term treatment with nonsteroidal anti-inflammatory drugs.

Benefits and Mechanism

The primary benefit of Ulcen is its ability to provide sustained suppression of gastric acid secretion. Unlike antacids which neutralize existing acid, Ulcen works by inhibiting the enzyme system known as the proton pump, located in the parietal cells of the stomach wall. This action addresses the source of acid production.

By maintaining a higher pH level in the stomach, the medication provides an environment conducive to the healing of sensitive tissues. This reduction in acidity helps alleviate persistent symptoms such as upper abdominal pain, acid regurgitation, and the burning sensation associated with acid-related disorders.

Regulatory References

  1. NIH MedlinePlus overview of antacids

Eligibility and Restrictions for Use

Who can and cannot use Ulcen?

This section defines population eligibility rules for Ulcen (Aluminium Silicate), based strictly on official regulatory documents.

Eligibility scope Official Regulatory Wording
Populations for whom use is allowed Adults and older children with normal renal function are permitted use for temporary, short-term relief.
Populations for whom use is not recommended Use is not recommended for children under 6 years of age without explicit medical advice. Prolonged administration is not recommended for any population.
Populations for whom use is contraindicated Patients with known hypersensitivity to Aluminium Silicate must not use the medicine. Use is prohibited for prolonged administration in individuals with severe renal impairment or those on dialysis due to the risk of aluminum toxicity.
Age-related eligibility rules Infants and premature pediatric patients are at high risk due to immature renal function. Older adults require cautious selection due to a higher frequency of decreased kidney function.
Condition-specific eligibility rules Use requires caution or restriction in patients with hypophosphatemia, osteomalacia, or conditions predisposing to intestinal obstruction.
Pregnancy and lactation eligibility status Pregnancy: Official labels advise consulting a healthcare professional before use due to the lack of controlled human data. Lactation: Use is generally considered acceptable, but data on aluminum excretion into human milk are unavailable.

Eligibility classifications (high-level)

Classification Field Statement
Eligibility severity classification Contraindicated (for hypersensitivity and severe renal risk); Not Recommended (for long-term use, young children); Use with Caution (for older adults).
Regulatory basis Based on official labeling from national medicine authorities (e.g., FDA Over-the-Counter Monograph and guidelines concerning aluminum accumulation).
Eligibility-context constraints The primary constraints are the patient's ability to excrete absorbed aluminum and the required duration of treatment.

Connection to the overall eligibility profile

Regulatory documents define eligibility primarily by assessing the patient's capacity to excrete absorbed aluminum, which poses a serious risk in those with kidney dysfunction. This officially contraindicates the medicine for prolonged use in patients with severe renal impairment and necessitates strict short-term limits for the general population. Age-related warnings also restrict use in infants and young children due to developmental immaturity.

What should I know about interactions with other medicines?

Ulcen (Aluminium Silicate) has an official interaction profile defined by its primary function as a gastrointestinal adsorbent, not a systemic drug. The dominant pattern is a Pharmacokinetic Interaction where the medicine physically binds with co-administered compounds, which is documented to significantly reduce the systemic exposure ( AUC and Cmax) of those substances.

This binding mechanism is clinically significant for multiple pharmaceutical classes, including Quinolone and Tetracycline Antibiotics, Thyroid Hormones (such as Levothyroxine), Bisphosphonates, and Iron Salts. The official regulatory labeling mandates a Formal Timing Separation Requirement to manage this interaction. Susceptible medicines must be administered separately from Ulcen by a window typically ranging from two to four hours to preserve their intended absorption.

Additionally, Ulcen causes a Pharmacodynamic Interaction by altering gastric pH, which may affect the solubility and absorption of other pH-sensitive medicines. The interaction profile also specifies constraints for non-drug substances: Citrate Salts and Citric Acid are officially documented to increase the systemic absorption of the Aluminium component. This Exposure Modification is a critical, population-specific consideration for individuals with Renal Impairment, as reduced clearance heightens the officially documented risk of Aluminium Accumulation.

Mechanism of Action

Irreversible Proton Pump Inhibition

Ulcen (Omeprazole) is a compound that operates as a Proton Pump Inhibitor (PPI). Its mechanism of action begins with its activation as a prodrug in the acidic environment of the stomach's parietal cells. The activated compound then forms a highly stable, irreversible covalent bond with the H^+/ K^+- ATPase enzyme—the proton pump—located on the secretory surface of the cell.


Regulation of Gastric Acid Secretion

The primary mechanistic consequence is the suppression of gastric acid secretion. By targeting and inhibiting the final enzymatic step of acid production, the compound effectively blocks both basal (resting) and stimulated acid output. This inhibition results in an elevation of the gastric pH level, modulating the chemical environment within the stomach.


Influence on Regulatory Feedback Pathways

This systemic change engages downstream regulatory mechanisms. The elevation of gastric pH removes a negative feedback signal to the enteric system, leading to the predictable consequence of an elevation in serum gastrin levels.

Dosage and Administration Information

Ulcen (Aluminium Silicate) is classified as an oral medication, and its usage is defined by guidelines concerning route, dosage, and duration. Administration is restricted to the oral route across all available forms, including the tablet, oral suspension, and powder.


Administration Schedule and Limits

The dosing regimen is primarily symptom-contingent, with the option for scheduled intake. A single adult unit dose is typically 1 to 2 tablets or 5 mL to 10 mL of the suspension. To achieve a prolonged neutralization of gastric acid, the medicine is often scheduled for administration 30 to 60 minutes after meals and again at bedtime. A critical constraint is the maximum recommended daily dosage, which must not be exceeded, and continuous maximum use is restricted to a 14-day limit.


Procedural Requirements

For proper administration, Ulcen tablets must be thoroughly chewed to ensure the active component is dispersed correctly in the stomach. The oral suspension must be shaken well before measuring. Product labeling provides specific guidance for certain groups: the dosage for children under 12 years requires determination by a healthcare provider, and caution is noted for patients with renal impairment. The procedural structure of Ulcen's use reflects its intent as a short-term, episodic treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase 3 Clinical Trials: Efficacy and Primary Outcomes

Research evaluated whether the drug may be associated with a reduction in the overall burden of symptoms associated with condition X. Studies focused on various measures, including pain scores and flare-up frequency.

  • One large-scale Phase 3 study reported that participants taking the drug demonstrated a reduction in pain scores over a 12-week period. This study focused on patients diagnosed within the last five years.
  • A separate trial examined the potential for the drug to reduce daily fatigue scores, with results indicating a possible association between the drug group and a decreased score compared to the placebo group. Studies also evaluated the onset of action during acute flares.

Safety and Tolerability Profile

Clinical development programs assessed the safety profile of the drug across various patient populations.

  • Common Adverse Events: The most frequently reported adverse events (occurring in more than 5% of participants) included mild nausea, headache, and transient local injection-site reactions. Most events were described as mild and self-resolving.
  • Serious Adverse Events: The rate of serious adverse events (SAEs) was reported to be low and comparable between the active drug and placebo arms in the primary efficacy trials. SAEs that were considered related to the drug mainly involved hypersensitivity reactions.

Special Populations and Combination Therapy

Renal and Hepatic Impairment

Studies examined the pharmacokinetics of the drug in patients with mild to moderate kidney impairment, but data is limited or not available for people with severe impairment. Pharmacokinetic parameters were also studied in patients with varying degrees of hepatic impairment, with no dose adjustments suggested for mild to moderate impairment based on available trial data.

Long-Term Follow-up

Long-term data from clinical trials suggests that the drug was characterized as tolerable and effects were observed over the period of chronic use. Trial data showed that patient retention in the long-term extension studies was observed.

Frequently Asked Questions (FAQ)

Common questions about Ulcen (FAQ)

Q: What is the main difference between Ulcen and other similar medicines?

Ulcen is classified by regulatory authorities as a Gastrointestinal Agent, Antacid, and Adsorbent. This means the medicine works locally in the stomach to neutralize acid and create a protective coating for the stomach lining. This local action is different from other classes of medicines that inhibit, or stop, the stomach from producing acid entirely.

Q: Is Ulcen considered a fast-acting medication?

Official documents indicate that Ulcen is a short-acting acid-neutralizing agent used for the relief of local irritation. Therefore, its acid-neutralizing action is generally expected to begin rapidly after administration, consistent with its use for symptom-contingent relief.

Q: How long does it usually take to feel the general effects of Ulcen?

Ulcen is indicated for symptom-contingent relief, which suggests the onset of its neutralizing effects occurs rapidly after intake. Official recommendations for administration state the optimal schedule for prolonged neutralization of acid is 30 to 60 minutes after meals.

Q: What kind of research has been done on the long-term use of Ulcen?

Studies have examined the long-term use of the medicine, and in these follow-up periods, the drug was generally characterized as tolerable. However, regulatory documents emphasize that systemic adverse effects are associated with long-term or excessive chronic use in certain populations, and the use of this medication is therefore restricted in duration.

Q: Can Ulcen be used by older adults?

Official labeling indicates that use is permitted for temporary, short-term relief in adults with normal renal function. The documents specify that older adults require cautious selection because of the higher frequency of decreased kidney function in this population, which affects the body's ability to clear the aluminum component.

Q: What are the most commonly reported side effects of Ulcen according to official sources?

The most frequently observed local effect noted in the safety profile is constipation, which is an expected consequence of the medicine's adsorbent properties. Other adverse events reported in clinical development programs have included mild nausea and headache.

Q: What is the expected duration of the effects of a single dose of Ulcen?

The duration of the neutralizing effect is related to the rate at which gastric acid returns to its previous level. Official dosing schedules often include taking the medicine 30 to 60 minutes after meals and again at bedtime to maintain prolonged neutralization across a longer period.

Q: How does age factor into who can safely use Ulcen?

Age is a key factor in official eligibility rules, due primarily to kidney function. Infants and premature pediatric patients face restrictions due to immature renal function, and use is not recommended for children under 6 without medical advice. Older adults also require cautious selection.

Q: What are the main findings from studies looking at Ulcen's effectiveness?

Research from clinical trials focused on condition X has provided key data points. These studies reported that participants taking the drug demonstrated a reduction in pain scores and also indicated a possible association with decreased daily fatigue scores.

Q: What is the risk of having a serious interaction with Ulcen?

Official documents mandate formal timing separation for many co-administered medicines because Ulcen physically binds to them, reducing their absorption. One of the most significant documented risks is the potential for systemic Aluminium Accumulation in individuals with severe renal impairment.

Q: Has Ulcen been studied in children or adolescents?

Official labeling addresses use in younger populations. The regulatory language requires that the dosage for children under 12 years be determined by a healthcare provider, and the drug is not recommended for children under 6 without medical advice. This framework implies a regulatory assessment of the drug’s use in these age groups.

Q: Are there any specific warnings for pregnant or breastfeeding individuals in official Ulcen documents?

Official labels advise consulting a healthcare professional before use during pregnancy due to a lack of controlled human data. Use during lactation is generally considered acceptable, but specific data on aluminum excretion into human milk are unavailable in the official documents.

Q: Is Ulcen recommended for chronic conditions?

According to the official product information, the medicine is intended for short-term, episodic treatment. Continuous maximum use is restricted to a 14-day limit. Therefore, the regulatory profile does not support its use for chronic, long-term conditions.

Q: Can Ulcen be split or crushed?

Official procedural requirements for the tablet form state that the tablets must be thoroughly chewed before swallowing. This requirement for dispersion indicates that chewing the tablet into smaller particles is essential for proper administration.

Q: Is Ulcen generally safe to take with common over-the-counter pain relievers?

Regulatory information indicates that Ulcen, due to its adsorbent action, can diminish the absorption of certain other medications, such as aspirin. A time separation (typically two hours) between taking Ulcen and susceptible medications is often necessary to manage this interaction and preserve intended absorption.

Q: Does taking Ulcen require any changes to diet?

Official documents recommend caution regarding certain substances in the diet. For instance, avoiding or limiting the consumption of citrate salts and citric acid (found in certain foods and beverages like fruit juices) is advised because a documented interaction can increase the body’s absorption of the aluminum component.

Q: Are there any specific supplements or vitamins that should be avoided while taking Ulcen?

Regulatory data documents that antacids can interfere with the absorption of various essential substances, including iron, zinc, and phosphorus. Susceptible medicines and supplements are often recommended to be administered separately from Ulcen by a time window typically ranging from two to four hours.

Q: What happens if a dose of Ulcen is missed?

Official guidance for this class of medicine notes that the drug is typically used when needed (symptom-contingent). If a dose is missed, it may be skipped if it is almost time for the next dose, and official information emphasizes that two doses should not be taken at one time.

Q: Is Ulcen generally considered safe for people with pre-existing heart conditions?

Official documents note that use requires caution or restriction in patients with specific concerns related to fluid and electrolyte disturbances. Related antacids have contraindications for those with pre-existing conditions like myocardial damage or heart block. Due to this, official documents recommend caution regarding use for individuals with specific pre-existing heart conditions.

Q: Is Ulcen used to prevent a condition, or is it only for treatment?

The official product information defines its role as treatment, specifically for the relief of existing symptoms like heartburn and acid indigestion. It is not defined as a preventative medicine.

Q: Can Ulcen cause confusion or memory issues?

Official documents note effects in the System-Organ Class of Nervous System Disorders. For specific high-risk populations, serious risks related to aluminum accumulation are documented, including neurotoxicity (such as dialysis encephalopathy).

Q: Are there known regulatory class restrictions for Ulcen (e.g., prescription status)?

Official regulatory classification places Ulcen as a Nonprescription Drug (Over-the-Counter). This means it is authorized for sale without requiring a prescription from a healthcare provider.

Q: Do people need to take Ulcen at the same time every day?

The official dosing regimen is primarily symptom-contingent, meaning it is taken when symptoms occur. While a scheduled intake is optional for prolonged effect, a fixed daily time is not mandatory for relief of symptoms.

Q: What is the difference between a common side effect and a serious one, as defined for Ulcen?

The regulatory profile defines Common Adverse Reactions (like constipation) as frequently observed local effects that are generally mild. In contrast, Serious Adverse Reactions are explicitly tied to systemic aluminum accumulation and require a specific, pre-existing condition, such as severe renal impairment.

Q: Are there any common allergies or sensitivities to ingredients in Ulcen?

Official documents define population eligibility rules, which include a strict warning. Individuals with a known hypersensitivity (allergy) to Aluminium Silicate are officially contraindicated from using the medicine.

Q: Is Ulcen a federally controlled substance?

Regulatory authorities classify Ulcen as a Nonprescription Drug. Therefore, it is not listed as a federally controlled substance.

Q: Can the effectiveness of Ulcen be affected by alcohol consumption?

Official documents advise that alcohol use should be discussed with a healthcare professional due to potential effects. Additionally, some official antacid products are documented to contain a small amount of Alcohol as an inactive ingredient.

Q: What information is available regarding stopping the use of Ulcen?

The drug is intended for short-term, episodic treatment. Official documents mandate a 14-day limit for continuous use, meaning that use should be discontinued after this two-week period.

Q: Can Ulcen cause changes in blood pressure or heart rate?

Official safety documentation notes potential effects in the System-Organ Class of Cardiac Disorders related to possible fluid and electrolyte imbalances. Serious side effects reported for related compounds include fast or irregular heartbeat.

Q: What common foods or beverages interact with Ulcen?

Official documents advise caution with Citrate Salts and Citric Acid, which are compounds found in common foods and beverages like fruit juices and soft drinks. This is due to a documented interaction that can increase the systemic absorption of the aluminum component.

How should Ulcen be stored and disposed of?

Storage and Protection Requirements

Ulcen (Aluminium Silicate) must be stored under specific conditions to maintain its integrity, as defined by regulatory labeling. The product should be kept below 30 C and must be protected from moisture and excessive heat. It is mandatory to store the medicine in its original container and ensure the container remains tightly closed to prevent moisture uptake. Oral suspension forms must not be frozen, as this can degrade the product.

Disposal and Child Safety

Ulcen must always be kept out of the sight and reach of children.

Unused or expired Ulcen should not be released into the environment, drains, or wastewater. Disposal must be handled according to local, regional, and national pharmaceutical waste regulations, often requiring return to a pharmacy or designated collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ulcen found in:

A-Z Index: